Agios Pharm

Yahoo Finance • 2 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO).  Such investors are advised to contact Danielle Peyton at... Full story

Yahoo Finance • 22 days ago

Top movers in Thursday's pre-market session

Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] GAINERS TICKER CHANGE COMMENT BRIA [https://www.chartmill.com/st... Full story

Yahoo Finance • 24 days ago

Commit To Buy Agios Pharmaceuticals At $30, Earn 34.9% Annualized Using Options

Investors eyeing a purchase of Agios Pharmaceuticals Inc (Symbol: AGIO) stock, but tentative about paying the going market price of $38.20/share, might benefit from considering selling puts among the alternative strategies at their disposa... Full story

Yahoo Finance • 29 days ago

CLF Crosses Above Average Analyst Target

In recent trading, shares of Cleveland-Cliffs Inc (Symbol: CLF) have crossed above the average analyst 12-month target price of $15.36, changing hands for $15.58/share. When a stock reaches the target an analyst has set, the analyst logi... Full story

Yahoo Finance • last month

US Outdoor Furniture and Kitchen Market Analysis Report 2025-2033 Featuring IKEA, Ashley Furniture, Brown Jordan, Keter, Agio, Lloyd Flanders, Barbeques Galore, Century, Kimball, Restoration Hardware

Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "United States Outdoor Furniture and Kitchen Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's offering. The... Full story

Yahoo Finance • 2 months ago

TD Cowen reiterates Buy rating on Agios Pharma stock amid safety concerns

Investing.com - TD Cowen has reiterated its Buy rating on Agios Pharmaceuticals (NASDAQ:AGIO) stock, currently trading at $36.03 with a market capitalization of $2.09 billion, despite recent attention around safety reports for the company’... Full story

Yahoo Finance • 2 months ago

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA’s Breakthrough Medicines Program Agios partnered with NewBridge Pharmaceuticals, a regional specialty company focused on the Middle East and North Africa, in 2024... Full story

Yahoo Finance • 2 months ago

Palantir, IDEXX Lead Market Cap Stock Movers on Monday

Monday’s market has seen significant activity, with stocks such as Palantir Technologies Inc (NASDAQ:PLTR) and Adv Micro Device (NASDAQ:AMD) showing notable gains, while Figma Inc (FIG) experienced a sharp decline. These movements refl... Full story

Yahoo Finance • 2 months ago

Traders are paying attention to the gapping stocks in Monday's session.

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps. [gap] GAP UP STOCKS TICKER CHANGE COMMENT... Full story

Yahoo Finance • 2 months ago

Agios falls as Leerink cites deaths linked to lead asset Pyrukynd

[Wall Street sign in Lower Manhattan, NYC] georgeclerk Shares of Agios Pharmaceuticals (NASDAQ:AGIO [https://seekingalpha.com/symbol/AGIO]) fell ~23% on Monday after Leerink Partners cited multiple deaths linked to the company’s lead asse... Full story

Yahoo Finance • 2 months ago

What's going on in today's pre-market session

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] GAINERS TICKER CHANGE COMMENT PBM [https://www.chartmill.com/stock... Full story

Yahoo Finance • 2 months ago

Agios Pharmaceuticals Inc (NASDAQ:AGIO) Reports Mixed Q2 2025 Results: Revenue Beat but Wider EPS Loss

Agios Pharmaceuticals Inc (NASDAQ:AGIO [https://www.chartmill.com/stock/quote/AGIO/profile]) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The biopharmaceutical company,... Full story

Yahoo Finance • 2 months ago

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

$12.5 million in second quarter PYRUKYND® (mitapivat) net revenues; ended second quarter with $1.3 billion dollars in cash, cash equivalents and marketable securitiesPYRUKYND sNDA for thalassemia under active review, with FDA PDUFA goal da... Full story

Yahoo Finance • 2 months ago

Agios Pharmaceuticals Q2 2025 Earnings Preview

* Agios Pharmaceuticals (NASDAQ:AGIO [https://seekingalpha.com/symbol/AGIO]) is scheduled to announce Q2 earnings results on Thursday, July 31st, before market open. * The consensus EPS Estimate is -$1.75 [https://seekingalpha.com/symb... Full story

Yahoo Finance • 2 months ago

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET

CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will... Full story

Yahoo Finance • 3 months ago

Agios pharma chief medical officer Gheuens sells $452,601 in stock

Agios Pharmaceuticals (NASDAQ:AGIO), which has seen a strong 20% return year-to-date, reported that Chief Medical Officer Sarah Gheuens sold 11,914 shares of common stock on July 9, 2025, for a total of $452,601. According to InvestingPro... Full story

Yahoo Finance • 3 months ago

Agios Appoints Dr. Jay Backstrom to Board of Directors

CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the appointment o... Full story

Yahoo Finance • 3 months ago

Agios pharma chief legal officer Burns sells $93k in stock

James William Burns, Chief Legal Officer of AGIOS PHARMACEUTICALS, INC. (NASDAQ:AGIO), sold 2,799 shares of common stock on June 24, 2025, at a price of $33.54, for a total transaction value of $93,878. The transaction comes as the stock,... Full story

Yahoo Finance • 3 months ago

Agios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat’s Market Potential

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is among the best NASDAQ stocks under $50 to buy. On Monday, analysts at TD Cowen reaffirmed their Buy rating on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), expressing confidence in the company’s mi... Full story

Yahoo Finance • 4 months ago

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that its managemen... Full story